Key points A 47-year-old French-speaking woman of African descent presented to the emergency department with a 1-week history of severe foot pain and difficulty walking. For the preceding 2 months she ...

It is being studied in phase 3 trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus ...

The Lupus Foundation of America (LFA) is excited to share that enrollment for the MiSLE (Mesenchymal Stromal Cells in Systemic Lupus Erythematosus) study was officially completed on February 21, 2025 ...

Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 31.15%, which has investors questioning if this is right time ...

Kris Aquino revealed her "pain and struggle" amid suffering from lupus flare fever for over two weeks now, appealing to the ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Fate Therapeutics, Inc.’s FATE share price has surged by 10.29%, which has investors questioning if this is right time to ...

Zacks Research boosted their Q1 2025 earnings per share estimates for Nektar Therapeutics in a research note issued on ...